Oncological applications of FDG PET imaging

Journal of Nuclear Medicine

Volumn 40, Issue 10, 1999, Pages 1706-1715

  Delbeke, Dominique ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

FDG PET; Oncologic imaging

Indexed keywords

FLUORODEOXYGLUCOSE F 18;

BREAST CARCINOMA; CANCER DIAGNOSIS; CANCER RECURRENCE; CANCER STAGING; DIAGNOSTIC VALUE; DRUG MONITORING; ENDOCRINE TUMOR; ESOPHAGUS CARCINOMA; HUMAN; LIVER CELL CARCINOMA; METASTASIS; PANCREAS CARCINOMA; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; REVIEW; SOFT TISSUE SARCOMA; STOMACH CARCINOMA; UROGENITAL TRACT CANCER;

BREAST NEOPLASMS; FLUORINE RADIOISOTOPES; FLUORODEOXYGLUCOSE F18; HUMANS; LIVER NEOPLASMS; LYMPHATIC METASTASIS; NEOPLASM RECURRENCE, LOCAL; NEOPLASM STAGING; NEOPLASMS; PANCREATIC NEOPLASMS; RADIOPHARMACEUTICALS; SENSITIVITY AND SPECIFICITY; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0032886668     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (100)

1. 18F]fluorodeoxyglucose and positron emission tomography. J Comput Assist Tomogr. 1989;13:1097-1098.
2. Wahl RL, Cody R, Hutchins GD, Mudgett E. Primary and metastatic breast carcinoma: initial clinical evaluation with PET with the radiolabeled glucose analog 2-[F-18]-fluorodeoxy-2-D-glucose (FDG). Radiology. 1991;179:765-770.
3. Tse NY, Hoh Ck, Hawkins RA, et al. The application of positron emission tomographic imaging with fluorodeoxyglucose to the evaluation of breast disease. Ann Surg. 1992;216:27-34.
4. Nieweg OE, Kim EE, Wong WH, et al. Positron emission tomography with fluorine-18-deoxyglucose in the detection and staging of breast cancer. Cancer. 1993;71:3920-3925.
5. Adler LP, Crowe JP, al-Kaisi NK, Sunshine JL. Evaluation of breast masses and axillary lymph nodes with [F-18]2-deoxy-2-fluoro-D-glucose PET. Radiology. 1993;187:743-750.
6. Hoh K, Hawkins RA, Glaspy JA, et al. Cancer detection with whole-body PET using [F-18]fluoro-2-deoxy-D-glucose. J Comput Assist Tomogr. 1993;17:582-589.
7. Dehdashti F, Mortimer JE, Siegel BA, et al. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays. J Nucl Med. 1995;36:1766-1774.
8. Avril N, Dose J, Janicke F, et al. Metabolic characterization of breast tumors with positron emission tomography using F-18 fluorodeoxyglucose. J Clin Oncol. 1996;14:1848-1857.
9. 18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability. Eur J Nucl Med. 1996;23:618-623.
10. Palmedo H, Bender H, Grunwald F, et al. Comparison of fluorine-18-fluorodeoxyglucose positron emission tomography and technetium-99m methoxyisobutylisonitrile scintimammography in the detection of breast tumors. Eur J Nucl Med. 1997;24:1138-1145.
11. Noh DY, Yun IJ, Kim JS, et al. Diagnostic value of positron emission tomography for detecting breast cancer. World J Surg. 1998;22:223-227.
12. Wahl RL, Helve MA, Chang AE, Andersson I. Detection of breast cancer in women after augmentation mammoplasty using fluorine-18-fluorodeoxyglucose-PET. J Nucl Med. 1994;35:872-875.
13. Wilking N, Rutqvist LE, Cartensen J, Mattson A, Skoog L. Prognostic significance of axillary nodal status in primary breast cancer in relation to the number of resected nodes. Acta Oncol. 1992;31:29-35.
14. March DE, Wechler RJ, Kurtz AB, Rosenberg AL, Needleman L. CT-pathologic correlation of axillary lymph nodes in breast carcinoma. J Comput Assist Tomogr. 1991;15:440-444.
15. Danforth DN. The role of axillary lymph node dissection in the management of breast cancer. In: DeVita UT, Hellman S, Rosenberg SA, eds. Principles and Practice of Oncology. 4th ed. Philadelphia, PA: JB Lippincott; 1993:1-16.
16. Silverstein MJ, Gierson ED, Waisman JR, Senofsky GM, Colburn WJ, Gamagami P. Axillary lymph node dissection for TIa breast carcinom: is it indicated? Cancer. 1994;73:664-673.
17. Utech CI, Young CS, Winter PF. Prospective evaluation of fluorine-18 fluorode-oxyglucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry. Eur J Nucl Med. 1996;23: 1588-1593.
18. Adler LP, Faulhaber PF, Schnur KC, Al-Kasi NC, Shenk RR. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET. Radiology. 1997;203:323-327.
19. Crippa F, Agresti R, Seregni E, et al. Prospective evaluation of fluorine-18-FDG PET in presurgical staging of the axilla in breast cancer. J Nucl Med. 1998;39:4-8.
20. Smith IC, Ogston KN, Whitford P, et al. Staging of the axilla in breast cancer: an accurate in vivo assessment using positron emission tomography with 2-(fluorine-18)-fluoro-2-deoxy-D-glucose. Ann Surg. 1998;228:220-227.
21. Bender H, Kirst J, Palmedo H, et al. Value of 18-ftuoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma. Anticancer Res. 1997;17:1687-1692.
22. Moon DP, Maddahi J, Silverman DHS, et al. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998;39:431-435.
23. 18FDG PET: differing metabolic activity in osteoblaslic and osteolytic lesions. J Clin Oncol. 1998;16:3375-3379.
24. Wahl RL, Zasadny K, Helvie M, et al. Metabolic monitoring of breast cancer chemohormonotherapy using positron emission tomography: initial evaluation. J Clin Oncol. 1993;11:2101-2111.
25. Jansson T, Westlin JE, Ahlstrom H, Lilja A, Langstrom B, Bergh J. Positron emission tomography studies in patients with locally advanced and/or metastatic breast cancer: a method for early therapy evaluation? J Clin Oncol. 1995;13:1470-1477.
26. Campbell JP, Wilson SR. Pancreatic neoplasms: how useful is evaluation with US? Radiology. 1988;167:341-344.
27. Diehl SJ, Lehman KJ, Sadick M, Lachman R, Georgi M. Pancreatic cancer: value of dual-phase helical CT in assessing resectability. Radiology. 1998;206: 373-378
28. Lu DSK, Reber HA, Krasny RM, Sayre J. Local staging of pancreatic cancer: criteria for unresectability of major vessels as revealed by pancreatic-phase, thin-section helical CT. AJR. 1997;168:1439-1444.
29. Brandt KR, Charboneau JW, Stephens DH, Welch TJ, Goellner JR. CT-and US-guided biopsy of the pancreas. Radiology. 1993;187:99-104.
30. McGuire GE, Pitt HA, Lillemoe KD, et al. Reoperative surgery for periampullary adenocarcinoma. Arch Surg. 1991;126:1205-1212.
31. Tyler DS, Evans DB. Reoperative pancreaticoduodenectomy. Ann Surg. 1994;219: 211-221.
32. Robinson EK, Lee JE, Lowy AM, et al. Reoperative pancreaticoduodenectomy for periampullary carcinoma. Am J Surg. 1996;172:432-438.
33. Thompson JS, Murayama KM, Edney JA, Rikkers LF. Pancreaticoduodenectomy for suspected but unproven malignancy. Am J Surg. 1994;169:571-575.
34. 18F-labelled deoxyglucose: method and first results. Nucl Med Commun. 1993;14:596-601.
35. Bares R, Klever P, Hauptmann S, et al. F-18-fluorodeoxyglucose PET in vivo evaluation of pancreatic glucose metabolism for detection of pancreatic cancer. Radiology. 1994;192:79-86.
36. Stollfuss JC, Glatting G, Friess H, Kocher F, Berger HG, Reske SN. 2-(fluorine-18)-fluoro-2-deoxy-D-glucose PET in detection of pancreactic cancer: value of quantitative image interpretation. Radiology. 1995;195:339-344.
37. Inokuma T, Tamaki N, Torizuka T, et al. Evaluation of pancreatic tumors with positron emission tomography and F-18 fluorodeoxyglucose: comparison with CT and US. Radiology. 1995;195:345-352.
38. Kato T, Fukatsu H, Ito K, et al. Fluorodeoxyglucose positron emission tomography in pancreatic cancer: an unsolved problem. Eur J Nucl Med. 1995;22:32-39.
39. Friess H, Langhans J, Ebert M, et al. Diagnosis of pancreatic cancer by 2[F-18]-fluoro-2-deoxy-D-glucose positron emission tomography. Gut. 1995;36: 771-777.
40. Ho CL, Dehdashti F, Griffeth LK, et al. FDG-PET evaluation of indeterminate pancreatic masses. J Comput Assist Tomogr. 1996;20:363-369.
41. Zimny M, Bares R, Fass J, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the differential diagnosis of pancreatic carcinoma: a report of 106 cases. Eur J Nucl Med. 1997;24:678-682.
42. Delbeke D, Rose M, Chapman WC, et al. Optimal interpretation of FDG PET significantly impacts the diagnosis, staging and management of pancreatic carcinoma. J Nucl Med. 1999:in press.
43. 18Fluorodeoxyglucose-positron emission tomography in the management of patients with suspected pancreatic cancer. Am Surg. 1999;229:729-737.
44. Wahl RL, Henry CA, Ethrer SP. Serum glucose: effects on tumor and normal tissue accumulation of 2-[F-18]-fluoro-2-deoxy-D-glucose in rodents with mammary carcinoma. Radiology. 1992;183:643-647.
45. Lindholm P, Minn H, Leskinen-Kallio S, et al. Influence of the blood glucose concentration on FDG uptake in cancer: a PET study. J Nucl Med. 1993;34:1-6.
46. Diedrichs CG, Staib L, Glatting G, Beger HG, Reske SN. FDG PET: elevated plasma glucose reduces both uptake and detection rate of pancreatic malignancies. J Nucl Med. 1998;39:1030-1033.
47. Weber G, Cantero A. Glucose-6-phosphatase activity in normal, precancerous. and neoplastic tissues. Cancer Res. 1955;15:105-108.
48. Weber G, Morris HP. Comparative biochemistry of hepatomas: part 3. Carbohydrate enzymes in liver tumors of different growth rates. Cancer Res. 1963;23:987-994.
49. Messa C, Choi Y, Hoh CK, et al. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr. 1992;16:684-689.
50. Okazumi S, Isono K, Enomoto D, et al. Evaluation of liver tumors using fluorine-18-fluorodeoxyglucose PET: characterization of tumor and assessment of effect of treatment. J Nucl Med. 1992;33:333-339.
51. Torizuka T, Tamaki N, Inokuma T, et al. In vivo assessment of glucose metabolism in hepatocellular carcinoma with FDG-PET. J Nucl Med. 1995;36: 1811-1817.
52. Delbeke D, Martin WH, Sandler MP, Chapman WC, Wright JK Jr, Pinson CW. Evaluation of benign vs. malignant hepatic lesions with positron emission tomography. Arch Surg. 1998;133:510-515.
53. Torizuka T, Tamaki N, Inokuma T, et al. Value of fluorine-18-FDG-PET to monitor hepatocellular carcinoma after interventional therapy. J Nucl Med. 1994;35:1965-1969.
54. 18F]FDG positron emission tomography. J Comput Assist Tomogr. 1990;14:370-374.
55. Griffeth LK, Dehdashti F, McGuire AH, et al. PET evaluation of soft-tissue masses with fluorine-18 fluoro-2-deoxy-D-glucose. Radiology. 1992;182:185-194.
56. Kern KA, Brunetti A, Norton JA, et al. Metabolic imaging of human extremity musculoskeletal tumors by PET. J Nucl Med. 1988;29:181-186.
57. 18F]FDG. J Comput Assist Tomogr. 1990;14:960-962.
58. Niweg O, Pruim J, van Ginkel RJ, et al. Fluorine-18-fluorodeoxyglucose PET imaging of soft-tissue sarcoma. J Nucl Med. 1996;37:257-261.
59. Jones DN, McCowage GB, Sostman HD, et al. Monitoring of neoadjuvant therapy response of soft-tissue and musculoskeletal sarcoma using fluorine-18-FDG-PET. J Nucl Med. 1996;37:1438-1444.
60. Van Ginkel RJ, Hoekstra HJ, Pruim J, et al. FDG-PET to evaluate response to hyperthermic isolated limb perfusion for locally advanced soft-tissue sarcoma. J Nucl Med. 1996;37:1438-1444.
61. Shreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2-[F-18]fluoro-D-glucose. Radiology. 1996;199:751-756.
62. Dehdashti F, Siegel BA, Griffeth LK, et al. Benign versus malignant intraosseous lesions: discrimination by means of PET with 2-[F-18] fluoro-2-deoxy-D-glucose. Radiology. 1996;200:243-247.
63. Guhlmann A, Brecht-Krauss D, Suger G, et al. Chronic osteomyelitis: detection with FDG-PET and correlation with histopathologic findings. Radiology. 1998;206:749-754.
64. Cook JR, Maiset MN, Fogelman I, et al. Fluorine-18-FDG PET in Paget's disease of bone. J Nucl Med. 1997;38:1495-1497.
65. Joensuu H, Ahonen A. Imaging of metastases of thyroid carcinoma with fluorine-18 fluorodeoxyglucose. J Nucl Med. 1987;28:910-914.
66. 18F-fluorodeoxyglucose imaging in preoperative diagnosis of thyroid malignancy. Eur J Nucl Med. 1988;13:502-506.
67. Sisson JC, Ackermann R, Meyer MA, Wahl RL. Uptake of FDG by thyroid cancer: implications for diagnosis and therapy. J Clin Endocrinol Metab 1993;77:1090-1094.
68. Scott GC, Meier DA, Dickinson CZ. Cervical lymph node metastasis of thyroid papillary carcinoma imaged with fluorine-18-FDG, technetium-99m-pertechnetate and iodine-131-sodium iodide. J Nucl Med. 1995;36:1843-1845.
69. 99mTc-sestamibi scintigraphy in diffentiated thyroid cancer. Thyroid. 1997;7:327-335.
70. Grunwald F, Schomburg A, Bender H, et al. Fluorine-18 fluorodeoxyglucose positron emission tomography in the follow-up of differentiated thyroid cancer. Eur J Nucl Med. 1996;23:312-319
71. Shulkin BL, Koeppe RA, Francis IR, Deeb GM, Lloyd RV, Thompson NW. Pheochromocytomas that do not accumulate netaiodobenzylguanidine: localization with PET and administration of FDG. Radiology. 1993;186:11-15.
72. Shulkin BL, Hutchinson RJ, Castle VP, Yar GA, Shapiro D, Sisson JC. Neuroblastoma: positron emission tomography with 2-[fluorine-18]-fluoro-2-deoxy-D-glucose compared with metaiodobenzylguanidine scintigraphy. Radiology. 1996;199:743-750.
73. Jadvar H, Segall GM. False-negative fluorine-18-FDG PET in metastatic carcinoid. J Nucl Med. 1997;38:1382-1383.
74. Abrams HL, Spiro R, Goldstein N. Metastases in carcinoma: analysis of 100 autopsied cases. Cancer. 1950;3:74-85.
75. Reinig JW, Doppman JL, Dwyer AJ, Johnson AP, Knop RH. Adrenal masses differentiated with MR imaging. Radiology. 1986;158:81-84.
76. Boland GW, Goldberg MA, Lee MJ, et al. Indeterminate adrenal mass in patients with cancer: evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose. Radiology. 1995;194:131-134.
77. 18F-fluorodeoxyglucose positron emission tomography. AJR. 1997;168:1357-1360.
78. Hoh CK, Seltzer MA, Franklin J, et al. Positron emission tomography in urological oncology. J Urol. 1998;159:347-356.
79. 18F)-fluoro-D-glucose: pilot animal and human studies. J Urol. 1991;146:1470-1474.
80. 18F) fluoro-D-glucose in bladder cancer: animal localization and initial patient positron emission tomography. J Urol. 1991;145:279-283.
81. Bachor R, Kotzerke J, Gottfried HW, Brandle E, Reske SN, Hautmann R. Positron emission tomography in diagnosis of renal cell carcinoma [in German]. Urologe A. 1996;35:146-150.
82. Miyauchi T, Brown RS, Grossman HB, et al. Correlation between visualization of primary renal cancer by FDG PET and histopathological findings [abstract]. J Nucl Med. 1996;37(suppl):64P.
83. Hoh CK, Figlin RA, Belldegrun A, et al. Evaluation of renal cell carcinoma with whole body FDG PET [abstract]. J Nucl Med. 1996:37(suppl):141P.
84. Bender H, Schomburg A, Albers P, Ruhlmann J, Biersack HJ. Possible role of FDG-PET in the evaluation of urologic malignancies. Anticancer Res. 1997;17: 1655-1660.
85. Effert PJ, Bares R, Handt S, et al. Metabolic imaging of untreated prostate cancer by positron emission tomography with 18-flourine-labeled deoxyglucose. J Urol. 1996;155:994-998.
86. Schreve PD, Grossman HB, Gross MD, Wahl RL. Metastatic prostate cancer: initial findings of PET with 2-deoxy-2[F-18]fluoro-D-glucose. Radiology. 1996; 199:751-756.
87. Laudenbacker C, Hofer C, Avril N, et al. F-18 FDG PET for differentiation of local recurrent prostate cancer and scar [abstract]. J Nucl Med. 1995;36(suppl): 198P.
88. Yeh SDJ, Imbriaco M, Garza D, et al. Twenty percent of bony metastases of hormone resistant prostate cancer are detected by PET-FDG whole body scanning [abstract]. J Nucl Med. 1995;36(suppl):198P.
89. Stephens AW, Gonin R, Hutchins GD, Einhorn LH. Positron emission tomography evaluation of residual radiographic abnormalities in postchemotherapy germ cell tumor patients. J Clin Oncol. 1996;14:1637-1641.
90. 18FDG positron emission tomography: prospects for detection and management. Eur J Nucl Med. 1995;22:508-513.
91. Sugawara Y, Zasadny KR, Grossman HB, et al. Germ cell tumor: differentiation of viable tumor, mature teratoma, and necrotic tissue with FDG PET and kinetic modeling. Radiology. 1999;211:249-256.
92. Wahl RL, Hutchins D, Robert J, et al. FDG-PET imaging of ovarian cancer: initial evaluation in patients [abstract]. J Nucl Med. 1991;32(suppl):982P.
93. Casey MJ, Gupta NC, Muths CK. Experience with positron emission tomography (PET) scans in patients with ovarian cancer. Gynecol Oncol. 1994;53:331-338.
94. 18F]FDG). Gynecol Oncol. 1993;51:197-204.
95. Bohdewiecz PJ, Scott GC, Juni JE, et al. Indium-111 oncoScint CR/OV and F-18 FDG in colorectal and ovarian carcinoma recurrences: early observations. Clin Nucl Med. 1995;20:230-236.
96. 18F-fluorodeoxyglucose positron emission tomography. AJR. 1997;168:417-424.
97. Block MI, Patterson GA, Sundaresan RS, et al. Improvement in staging of esophageal cancer with the addition of positron emission tomography. Ann Thorac Surg. 1997;64:770-776.
98. Luketich JD, Schauer PR, Meltzer CC, et al. Role of positron emission tomography in staging esophageal cancer. Ann Thorac Surg. 1997;64:765-769.
99. Couper GW, McAteer D, Wallis F, et al. Detection of response to chemotherapy using positron emission tomography in patients with oesophageal and gastric cancer. Br J Surg. 1998;85:1403-1406.
100. Yeung HWD, Macapinlac H, Karpeh M, Rinn RD, Larson SM. Accuracy of FDG-PET in gastric cancer: preliminary experience. Clin Positron Imaging. 1998;1:213-221.